Abstract: The invention provides methods of making and using compositions for establishing mixed chimerism in a subject that include CD34+ cells and CD3+ cells derived from an apheresis product obtained from a subject that has previously donated a solid organ.
Abstract: The invention provides cellular compositions that contain CD34+ cells derived from bone marrow of a decease donor and CD3+ cells derived from non-bone marrow of the deceased donor. The compositions are useful to promote mixed chimerism in recipients of solid organ transplants. The invention also provides methods of making and using such compositions. In certain embodiments, the invention further provides methods of analyzing and preparing blood and blood components from a deceased donor for use in compositions of the invention to promote mixed chimerism in solid organ transplant recipients.
Type:
Grant
Filed:
September 18, 2019
Date of Patent:
November 14, 2023
Assignee:
MEDEOR THERAPEUTICS, INC.
Inventors:
Michael Zdanowski, Colby Suire, D. Scott Batty, Jr.
Abstract: The invention provides compositions for establishing mixed chimerism in a subject. The compositions include CD34+ cells that have been column-purified from an apheresis product and CD3+ cells from an apheresis product that have not been purified through a column. The invention also provides methods of making and using such compositions.
Abstract: Provided are improved methods for grafting donor derived CDS 4+ cells in an organ transplant recipient comprising administration CD3+ cells together with a calcineurin inhibitor in an effective amount to reduce or prevent an immune system of the recipient from rejecting the CD3+ cells from the donor, thereby enabling the CD3+ cells of the donor to facilitate engraftment of the CDS 4+ cells from the donor. In certain embodiments, the effective amount of the calcineurin inhibitor provided to reduce or prevent the immune system of the recipient from rejecting the CD3+ cells of the donor is lower than an amount provided for protecting the organ of the donor from rejection by the immune system of the recipient.
Abstract: The invention provides cellular compositions that contain CD34+ cells derived from bone marrow of a decease donor and CD3+ cells derived from non-bone marrow of the deceased donor. The compositions are useful to promote mixed chimerism in recipients of solid organ transplants. The invention also provides methods of making and using such compositions. In certain embodiments, the invention further provides methods of analyzing and preparing blood and blood components from a deceased donor for use in compositions of the invention to promote mixed chimerism in solid organ transplant recipients.
Type:
Grant
Filed:
September 18, 2019
Date of Patent:
September 6, 2022
Assignee:
MEDEOR THERAPEUTICS, INC.
Inventors:
Michael Zdanowski, Colby Suire, D. Scott Batty, Jr.
Abstract: The invention provides methods of treating non-cancerous disorders in a subject by providing the subject with compositions containing hematopoietic cells. In certain embodiments, the compositions include CD34+ cells and CD3+ cells. In certain embodiments, the compositions include CD34+ cells and facilitating cells. The methods are useful for treating blood cell disorders and other disorders that can be ameliorated by providing donor hematopoietic cells.
Abstract: The invention provides compositions for establishing mixed chimerism in a subject. The compositions include CD34+ cells that have been column-purified from an apheresis product and CD3+ cells from an apheresis product that have not been purified through a column. The invention also provides methods of making and using such compositions.
Abstract: The invention provides methods of making and using compositions for establishing mixed chimerism in a subject that include CD34+ cells and CD3+ cells derived from an apheresis product obtained from a subject that has previously donated a solid organ.